Southern Capital Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 25.7% within the third quarter, HoldingsChannel stories. The fund owned 1,791 shares of the corporate’s inventory after promoting 618 shares in the course of the quarter. Southern Capital Advisors LLC’s holdings in Johnson & Johnson had been value $290,000 on the finish of the latest reporting interval.
A number of different giant traders have additionally lately purchased and offered shares of the enterprise. Summit Wealth Companions LLC grew its place in Johnson & Johnson by 0.6% within the second quarter. Summit Wealth Companions LLC now owns 10,007 shares of the corporate’s inventory valued at $1,463,000 after buying an extra 61 shares in the course of the interval. Powers Advisory Group LLC boosted its stake in shares of Johnson & Johnson by 0.6% within the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the corporate’s inventory valued at $1,538,000 after buying an extra 61 shares within the final quarter. Residents & Northern Corp grew its holdings in shares of Johnson & Johnson by 3.5% within the 2nd quarter. Residents & Northern Corp now owns 1,884 shares of the corporate’s inventory value $275,000 after buying an extra 63 shares over the last quarter. Eagle Wealth Methods LLC elevated its place in shares of Johnson & Johnson by 2.8% in the course of the third quarter. Eagle Wealth Methods LLC now owns 2,294 shares of the corporate’s inventory value $372,000 after buying an extra 63 shares within the final quarter. Lastly, Epic Belief Funding Advisors LLC lifted its holdings in Johnson & Johnson by 3.6% in the course of the 2nd quarter. Epic Belief Funding Advisors LLC now owns 1,831 shares of the corporate’s inventory valued at $268,000 after buying an extra 64 shares over the last quarter. Hedge funds and different institutional traders personal 69.55% of the corporate’s inventory.
Analyst Upgrades and Downgrades
A number of analysts have lately weighed in on the inventory. Sanford C. Bernstein raised their worth goal on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Citigroup boosted their goal worth on Johnson & Johnson from $180.00 to $185.00 and gave the inventory a “purchase” score in a report on Wednesday, October sixteenth. The Goldman Sachs Group diminished their goal worth on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” score on the inventory in a report on Friday, July nineteenth. TD Cowen diminished their goal worth on Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score on the inventory in a report on Thursday, July 18th. Lastly, StockNews.com raised Johnson & Johnson from a “purchase” score to a “strong-buy” score in a report on Saturday, September 14th. Six analysis analysts have rated the inventory with a maintain score, seven have given a purchase score and one has issued a robust purchase score to the corporate’s inventory. Based mostly on information from MarketBeat, Johnson & Johnson presently has a consensus score of “Reasonable Purchase” and a median goal worth of $175.93.
Get Our Newest Evaluation on Johnson & Johnson
Insider Shopping for and Promoting at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker offered 5,635 shares of the corporate’s inventory in a transaction on Friday, August thirtieth. The shares had been offered at a median worth of $165.06, for a complete transaction of $930,113.10. Following the completion of the sale, the vice chairman now owns 18,973 shares within the firm, valued at roughly $3,131,683.38. The commerce was a 0.00 % lower of their place. The sale was disclosed in a authorized submitting with the SEC, which is accessible by this hyperlink. Company insiders personal 0.16% of the corporate’s inventory.
Johnson & Johnson Inventory Down 0.9 %
NYSE:JNJ opened at $160.14 on Wednesday. The inventory’s fifty day transferring common worth is $163.45 and its two-hundred day transferring common worth is $155.28. Johnson & Johnson has a 52-week low of $143.13 and a 52-week excessive of $168.85. The corporate has a debt-to-equity ratio of 0.44, a fast ratio of 0.85 and a present ratio of 1.07. The corporate has a market cap of $385.41 billion, a price-to-earnings ratio of 9.98, a P/E/G ratio of two.90 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final posted its quarterly earnings information on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The agency had income of $22.47 billion for the quarter, in comparison with the consensus estimate of $22.17 billion. Johnson & Johnson had a return on fairness of 35.46% and a web margin of 19.14%. The enterprise’s income for the quarter was up 5.2% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the prior 12 months, the enterprise earned $2.66 EPS. On common, analysts anticipate that Johnson & Johnson will publish 9.94 EPS for the present 12 months.
Johnson & Johnson Dividend Announcement
The agency additionally lately introduced a quarterly dividend, which can be paid on Tuesday, December tenth. Shareholders of document on Tuesday, November twenty sixth can be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of three.10%. The ex-dividend date is Tuesday, November twenty sixth. Johnson & Johnson’s payout ratio is 30.92%.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare subject worldwide. The corporate’s Revolutionary Medication section presents merchandise for numerous therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Additional Studying
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Each day – Enter your e mail tackle beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE day by day e mail publication.
